Cytogen deal

CYTO (Princeton, N.J.) finalized its previously announced agreement under which DuPont Merck Pharmaceutical Co.’s radiopharmaceuticals division will manufacture and market CYTO’s Samarium 153 EDTMP in the U.S. for the relief of pain in patients with bone metastases. ...